Acquisition - HealthQuill

Johnson & Johnson plans to acquire Israel’s privately-held V-Wave Ltd., for an upfront payment of $600 million, according to a statement from the US-based company.

J&J plans to acquire Israel’s V-Wave by paying $600 million upfront

Johnson & Johnson plans to acquire Israel’s privately-held V-Wave Ltd., for an upfront payment of $600 million, according to a statement from the.

by HealthQuill
August 20, 2024
0 Comments

India’s Mankind Pharma will buy Mumbai-based Bharat Serums and Vaccines for 136 billion rupees ($1.63 billion), according to a company statement.

Drugs Health Pharma

Mankind Pharma buys Bharat Serum and Vaccines for $1.6 billion

India’s Mankind Pharma will buy Mumbai-based Bharat Serums and Vaccines for 136 billion rupees ($1.63 billion), according to a company statement.

by HealthQuill
July 26, 2024
0 Comments

Agilent Technologies Inc., will acquire Canada-based Biovectra, a contract development and manufacturing company, for $925 million, according to a company statement.

Drugs Health Pharma

US-based Agilent Technologies to acquire Canada’s Biovectra for $925m

HQ Team July 23, 2024: Agilent Technologies Inc., will acquire Canada-based Biovectra, a contract development and manufacturing company, for $925 million, according to.

by HealthQuill
July 23, 2024
0 Comments

AstraZeneca announced the completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, for $2.4 billion.

Drugs Health Pharma

AstraZeneca completes $2.4 billion acquisition of Fusion Pharma

AstraZeneca announced the completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, for $2.4 billion.

by HealthQuill
June 4, 2024
0 Comments

Johnson & Johnson has agreed to buy the rights for an investigational skin disorder treatment from Numab Therapeutics for $1.25 billion.

Drugs Health Pharma

J & J to buy rights for experimental skin disorder drug for $1.25 billion

Johnson & Johnson has agreed to buy the rights for an investigational skin disorder treatment from Numab Therapeutics for $1.25 billion.

by HealthQuill
May 30, 2024
0 Comments

Johnson & Johnson will acquire Proteologix, Inc., a privately-held biotechnology company, for $850 million in cash, according to a statement.

Drugs Health Pharma

Johnson & Johnson to buy Proteologix Inc., for $850 million in cash

HQ Team May 17, 2024: Johnson & Johnson will acquire Proteologix, Inc., a privately-held biotechnology company, for $850 million in cash, according to.

by HealthQuill
May 17, 2024
0 Comments

Britain’s Competition and Markets Authority (CMA) expressed concerns over Theramex's planned acquisition of Femoston and Duphaston stating it may reduce competition and choice for hormone replacement therapy (HRT) treatments in the country.

Drugs Health Pharma

Britain’s CMA raises concern over Theramex’s Femoston buy

HQ Team April 4, 2024: Britain’s Competition and Markets Authority (CMA) expressed concerns over Theramex’s planned acquisition of Femoston and Duphaston stating it.

by HealthQuill
April 4, 2024
0 Comments

Novo Nordisk, one of the world’s most valuable companies, will acquire Germany-based Cardior Pharmaceuticals, a firm that specialises in heart diseases, for up to 1.03 billion euros ($1.1 billion).

Drugs Health Pharma

Novo to buy Cardior for $1.1b to expand cardiovascular segment

HQ Team March 25, 2024: Novo Nordisk, one of the world’s most valuable companies, will acquire Germany-based Cardior Pharmaceuticals, a firm that specialises.

by HealthQuill
March 25, 2024
0 Comments

Anglo-Swedish drugmaker, AstraZeneca will acquire clinical-stage Fusion Pharmaceuticals for $2 billion in cash to get access to the latter’s radioconjugates to treat cancer.

Drugs Health Pharma

AstraZeneca to acquire Fusion Pharmaceuticals for $2 billion in cash

HQ Team March 20, 2024: Anglo-Swedish drugmaker, AstraZeneca will acquire clinical-stage Fusion Pharmaceuticals for $2 billion in cash to get access to the.